Please check your internet connection and try again.
# Eplarestat
## Overview
- **Classification**: Aldose Reductase Inhibitor
- **Mechanism**: Inhibits aldose reductase, an enzyme that converts glucose to sorbitol. This prevents sorbitol accumulation in cells, a factor in diabetic complications.
## Primary Indications
1. **Diabetic Peripheral Neuropathy (DPN)** - Management of subjective symptoms of DPN (approved in Japan).
## Adult Dosing
### Standard Dosing
**Diabetic Peripheral Neuropathy**
- **Dose**: **150 mg**
- **Frequency**: Once daily (**QD**)
- **Route**: Oral (PO)
- **Duration**: Long-term for symptom control.
### Dose Adjustments
- **Renal Impairment**: No specific dose adjustment recommended. Use with caution in severe impairment.
- **Hepatic Impairment**: No specific dose adjustment recommended. Use with caution in severe impairment.
- **Elderly Patients**: No specific dose adjustment needed. Monitor for adverse effects.
## Pediatric Dosing
**Note**: Safety and efficacy of eplarestat have **not been established** in pediatric patients. Use is generally not recommended.
### Neonates (0-28 days)
- **Dose**: Not established
- **Frequency**: Not established
- **Maximum**: Not applicable
- **Special Notes**: Not recommended due to lack of data.
### Infants (1-12 months)
- **Dose**: Not established
- **Frequency**: Not established
- **Maximum**: Not applicable
### Children (1-12 years)
- **Dose**: Not established
- **Frequency**: Not established
- **Maximum**: Not applicable
### Adolescents (13-18 years)
- **Dose**: Not established
- **Maximum**: Not applicable. Use not recommended.
## Safety Information
### Contraindications
- **Absolute**: Hypersensitivity to eplarestat or any component of the formulation.
- **Absolute**: Pregnancy and lactation (due to lack of safety data).
- **Relative**: Severe hepatic impairment (monitor closely if used).
### Common Adverse Effects
- **Very Common (>10%)**: None specifically cited.
- **Common (1-10%)**: Nausea, abdominal pain/discomfort, diarrhea, headache, rash, elevated liver enzymes (AST, ALT).
- **Serious but Rare**: Hypersensitivity reactions (e.g., anaphylaxis), severe hepatotoxicity.
### Key Drug Interactions
- **No significant drug-drug interactions** are widely reported.
- **Other glucose-lowering agents**: Can be used concomitantly; monitor blood glucose.
- Eplarestat is not a major substrate, inducer, or inhibitor of CYP450 enzymes.
## Monitoring & Follow-up
- **Before Treatment**: Baseline liver function tests (LFTs: AST, ALT).
- **During Treatment**: Periodically monitor LFTs (e.g., every 3-6 months). Monitor subjective DPN symptoms.
- **Clinical Signs**: Watch for signs of liver injury (fatigue, dark urine, jaundice, right upper quadrant pain).
## Clinical Pearls
- 💡 **Tip 1**: Eplarestat targets symptoms of DPN; it does not cure diabetes or reverse nerve damage.
- 💡 **Tip 2**: Consistent daily administration is key. Symptomatic improvement may take several weeks to months.
- 💡 **Tip 3**: Emphasize the importance of strict glycemic control as foundational to managing diabetic complications.
- 💡 **Tip 4**: Eplarestat is primarily approved and available in Japan; not widely approved in other regions.
> **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.
